Overdose Disparities Series: Communityinformed Strategies for Addressing Non-Fatal and Fatal Overdose within Black/African American Populations Part 4

Chuck Klevgaard, Prevention Manager, Great Lakes PTTC

Kathie Kane-Willis Director of Research and Policy for the Research and Policy Center at the Chicago Urban League

Kareem Butler Director of Learning and Evaluation for the Research and Policy Center, at the Chicago Urban League

Brought To You By:





The Great Lakes ATTC, MHTTC, and PTTC are funded by the Substance Abuse and Mental Health Services Administration (SAMHSA under the following cooperative agreements:

Great Lakes ATTC: 1H79TI080207-03

Great Lakes MHTTC: IH79SM-081733-01

Great Lakes PTTC: 1H79SP081002-01

Disclaimer


This presentation was prepared for the Great Lakes MHTTC under a cooperative agreement from the Substance Abuse and Mental Health Services Administration (SAMHSA). All material appearing in this presentation, except that taken directly from copyrighted sources, is in the public domain and may be reproduced or copied without permission from SAMHSA or the authors. Citation of the source is appreciated. Do not reproduce or distribute this presentation for a fee without specific, written authorization from the Great Lakes PTTC.

At the time of this presentation, Tom Coderre, serves as Acting SAMHSA Assistant Secretary. The opinions expressed herein are the views of the speakers and do not reflect the official position of the Department of Health and Human Services (DHHS), SAMHSA. No official support or endorsement of DHHS, SAMHSA, for the opinions described in this document is intended or should be inferred.

January 2021

The use of affirming language inspires hope. LANGUAGE MATTERS. Words have power. PEOPLE FIRST.

The PTTC Network uses affirming language to promote the application of evidence-based and culturally informed practices.



Thank You for Joining Us!

A few housekeeping items:

- If you are having technical issues, please individually message Kristina Spannbauer or Stephanie Behlman in the chat section and they will be happy to assist you.
- Please put any questions for the speaker or comments in the Q & A section, also at the bottom of the screen. We will respond to questions during the presentation.
- We will be using automated transcriptions for todays webinar.

Thank You for Joining Us!

A few more housekeeping items:

- You will be directed to a link at the end of the presentation to a very short survey – we would really appreciate it if you could fill it out. It takes about 3 minutes.
- We are recording this session and it will be available on our website in a couple of weeks.
- Certificates of attendance will be sent out to all who attended the full session. They will take about 2 weeks.

Follow Us On Social Media!

Facebook and Twitter:

- @GreatLakesATTC
- @GMhttc
- @GLPTTC



Speaker Introductions







5-10-21

Overdose Disparities Series: Communityinformed Strategies for Addressing Non-Fatal and Fatal Overdose within Black/African American Populations

Whitewashed: Black Opioid Crisis in Perspective

Kathie Kane-Willis
Director of Research + Policy
Kareem Butler
Director of Learning + Evaluation
Research & Policy Center




Research Notes

- ➤ Black race refers to individuals who are identified in publicly available data sets as Black or African American
- White race includes ethnicities such as Latinx or Hispanic
- The majority of overdose deaths occur between these two groups
- Latinx deaths occur at lower rates than Whites or Blacks, generally, although
 - There is a lot of regional variation
- Rates are not age adjusted



Fatal Opioid OD by Rate and Race 2003-2019


CDC Wonder Analysis





Synthetic (e.g. Fentanyl and analogues) 2003- 2019 -CDC Wonder Analysis








Synthetic Opioid Overdose Deaths by Rate among Blacks and Whites 2003 to 2019

- CDC Wonder Analysis





Fentanyl among Decedents in Cook County (Chicago)2015 -2020

	2015	2016*	2018	2019	2020^	Change Time
No Fentanyl	85.1%	50.7%	26.4%	26%	19.2%	-77%
Yes	14.9%	49.3%	73.6%	73%	80.8%	441%

^{*}year Blacks became more prevalent among Decedents




[^] represents a partial year

Stimulant Overdose Deaths by Rate among Blacks and Whites 2003 to 2019

- CDC Wonder Analysis

US Stimulant OD deaths by Race





States with the Highest Disparity between Black and White Rates for Opioid Overdose Deaths (2019)

- CDC Wonder Analysis

violider Alialysis							
	Rank		Black	White	Difference(All	#
		State	Rate	Rate	b-w)	Groups	Deaths
	1	Missouri	42.3	15.6	26.7	18.3	1101
	2	Illinois	37.8	15.6	22.2	17.7	2222
	3	West Virginia	60.4	39.1	21.3	38.9	694
	4	Wisconsin	31.8	15.1	16.7	18.8	891
	5	Michigan	30.4	16.6	13.8	17.9	1742
	6	Iowa	16.4	5.0	11.4	5.4	164
	7	Minnesota	17.7	6.3	11.4	7.6	367
	8	Maryland	44.7	35.6	9.1	35.3	2101
	9	New Jersey	38.1	29.4	8.7	28.3	2480
	10	Pennsylvania	30.6	24.1	6.5	23.7	2993
	11	Colorado	16.3	11.4	4.9	11.6	640
	12	Ohio	35.4	30.8	4.6	30	3482
	13	Washington	15.4	11.7	3.7	11	753
	14	Arizona	21.5	18.5	3	17.8	1195
	15	California	12.3	9.6	2.7	8.3	3035
	NA	US rate	17.4	16.5	0.9	16.6	49038



Differences in Route of Administration among Publicly Funded Treatment Admissions for Heroin by Race – United States, 2018

Route	Black	White
Oral	1%	1%
Smoking	3%	7%
Snorting	66%	18%
Injection	29%	73%



Differences in Route of Administration among Publicly Funded Treatment Admissions for Heroin by Race – Midwest, 2018

Route	Black	White
Oral	1%	1%
Smoking	2%	3%
Inhalation	77%	21%
Injecting	20%	76%
Other	0%	0%



Differences in Route of Administration among Publicly Funded Treatment Admissions for Heroin by Race – West, 2018

Route	Black	White
Oral	2%	2%
Smoking	23%	28%
Inhalation	30%	3%
Injecting	44%	67%
Other	1%	0%



Differences in Route of Administration among Publicly Funded Treatment Admissions for Heroin by Race – Illinois, 2018

Route	Black	White
Oral	1%	1%
Smoking	2%	1%
Inhalation	90%	28%
Injecting	7%	69%



Differences in Route of Administration among Publicly Funded Treatment Admissions for Heroin by Race – Minnesota, 2018

Route	Black	White
Oral	1%	1%
Smoking	9%	12%
Inhalation	57%	13%
Injecting	33%	74%



Why Do Race Differences in the Route of Administration Matter?

- Much naloxone is provided through syringe service programs, which may better serve the needs of injectors than snorters or smokers
- ➤ Harm reduction services are mostly (or exclusively) provided through SSPs and Black people are more likely to have stigma related to needle useage
- Many SSPs do not have staffs/leaderships of color
- ➤ IM naloxone might not be useful for Black people who do not inject drugs.



Drivers of Increased Overdose Deaths among Blacks

- Increasing fentanyl adulteration in heroin, cocaine, and other drugs including pills which might be tied to proximity to drug market or social networks
 - Some decedents may not have tolerance to opioids because they didn't mean to use an opioid
- Less access to harm reduction services because most if not all are conducted through SSPs
 - > Higher stigma among blacks for injection drug use
 - Much lower rates of injecting
- IM naloxone might not work for people who do not inject (complicated delivery system)
 - > Fear of police
 - Fear of stigma



Drivers of Increased Overdose Deaths among Blacks (Continued 1)

- Untreated pain among Black people and increased rates of disability
- Social Determinants of health, health disparities
 - **Pollution**
 - Food deserts (gut mind connection)
 - > Access to medical care, pharmacy deserts
- ➤ Lack of compassionate and/or overtly discriminatory care and by medical providers drives people away from care



Drivers of Increased Overdose Deaths among Blacks (Continued 2)

- Lack of medication assisted treatment, especially, buprenorphine located in black communities
- Mass incarceration
 - Negative experiences with coercive non-evidenced based treatment may deter people from seeking treatment
 - ➤ Loss of tolerance, after detention or incarceration substantially increases the risk of fatal overdose especially with opioids
- Pre-existing medical conditions due to systemic racism and trauma
- Lack of Black medical, treatment and harm reduction providers

Principles

- ✓ African American people, families and communities cannot be excluded from narratives told about the opioid epidemic, opioid overdose deaths or the needs of impacted individuals, families and communities.
- ✓ The development and implementation of national and local public health policy and plans must include the participation of Black individuals, families, leaders and/or organizations through all phases of the planning process.
- ✓ Public health and treatment interventions must be tailored to address the experiences and needs of the African American community



Legal and Implementation Implications

- Despite having strong overdose prevention laws, naloxone (the OD reversal drug) is not being distributed in African American communities
- While Medicaid (in IL) covers MAT and naloxone, there may be gaps in knowledge about these medications used to treat OUD.
- ➤ Buprenorphine capacity is low for many reasons, including the underfunding of treatment generally during the grants process.
- ➤ In Chicago, and many other places, heroin arrests are concentrated in the same place where the highest rates of deaths are highest



Policy Recommendations

- ✓ Ensure access to NASAL naloxone by people who do not inject drugs
- ✓ Decriminalize Simple Drug Possession
- ✓ Stop the Targeting of Black people by the police
- ✓ Create Funding streams for Black Lead and developed Harm Reduction Initiatives
- **✓** More Black doctors + more Black treatment providers
- ✓ More research needed on Racial differences in harm reduction access, use patterns, and purchasing patterns.
- ✓ Consider safe supply



Questions?
Comments?
Want a copy of the paper?
Email us,
Kathie:

kkanewillis@chiul.org

Or Kareem:

kbutler@chiul.org

